| United States | |
| 130 | |
| Development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. | |
| Zalviso, our lead program, has completed Phase 3 development and an NDA has been submitted to the FDA seeking its approval. The product was developed to address some of the challenges associated with intravenous patient-controlled analgesia (IV PCA), which is the standard means of treating moderate-to-severe acute pain in the hospital setting. ARX-02 is a potential new treatment option for patients who suffer from breakthrough pain (BTP) due to cancer that has completed Phase 2 development. ARX-03 is a sublingual product candidate designed to provide non-invasive mild sedation, anxiety reduction and pain relief in patients prior to a painful procedure in a physicians office. ARX-03 has completed Phase 2 development. ARX-04 a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury. |
|
| MORRIS Timothy | |
| www.acelrx.com | |
| ACRX:US |
Fiche créée le 10/04/2016 par 
Guillaume vue 35 fois.